tiprankstipranks
Bright Minds and Firefly Neuroscience Renew Collaboration
Company Announcements

Bright Minds and Firefly Neuroscience Renew Collaboration

Story Highlights

Bright Minds Biosciences (TSE:DRUG) has released an update.

Pick the best stocks and maximize your portfolio:

Bright Minds Biosciences is teaming up again with Firefly Neuroscience to analyze EEG data from their Phase 2 trial of BMB-101, aimed at treating Absence Epilepsy and Developmental Epileptic Encephalopathy. This collaboration leverages advanced AI technology to potentially offer innovative solutions for drug-resistant epilepsy patients. BMB-101 is a promising compound that has shown efficacy in preclinical studies and may provide sustained relief for hard-to-treat epilepsy cases.

For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyBright Minds Biosciences initiated with an Outperform at Baird
TipRanks Canadian Auto-Generated NewsdeskBright Minds Biosciences to Present Novel Epilepsy Data
TheFlyBright Minds Biosciences participates in a conference call with Truist
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App